Treatment of mice with GRP78 intravenously or subcutaneously during the active phase of the collagen induced arthritis model reduced disease severity and led to increased IL-4, IL-5, and IL-10 (associated with dampening immune responses) production [209]. This evidence concerns the gene HSPA5 and arthritic joint disease.